Nuvectis Pharma, Inc.
NVCT
$9.10
-$0.395-4.16%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.95M | 1.54M | 1.70M | 1.74M | 2.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.45M | 4.36M | 4.64M | 4.40M | 5.87M |
| Operating Income | -6.45M | -4.36M | -4.64M | -4.40M | -5.87M |
| Income Before Tax | -6.25M | -4.15M | -4.43M | -4.17M | -6.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.25M | -4.15M | -4.43M | -4.17M | -6.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.25M | -4.15M | -4.43M | -4.17M | -6.62M |
| EBIT | -6.45M | -4.36M | -4.64M | -4.40M | -5.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.35 | -0.24 | -0.26 | -0.25 | -0.41 |
| Normalized Basic EPS | -0.22 | -0.15 | -0.16 | -0.16 | -0.22 |
| EPS Diluted | -0.35 | -0.24 | -0.26 | -0.25 | -0.41 |
| Normalized Diluted EPS | -0.22 | -0.15 | -0.16 | -0.16 | -0.22 |
| Average Basic Shares Outstanding | 17.76M | 17.23M | 16.90M | 16.56M | 16.20M |
| Average Diluted Shares Outstanding | 17.76M | 17.23M | 16.90M | 16.56M | 16.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
